Patents Assigned to JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD
  • Patent number: 10392352
    Abstract: The present invention discloses an etomidate derivative of Formula 1, or a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, a pharmaceutical composition and a kit comprising the same, as well as intermediates and methods for preparing the same, and use thereof. The etomidate derivative of the present invention not only has good anesthetic activity, rapid onset, and short duration of action, but also shows little inhibition to the secretion of corticosteroids in animals, and therefore has both favorable anesthetic effect and safety profiles.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: August 27, 2019
    Assignee: JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD.
    Inventors: Qingeng Li, Tao Wang, Lingguo Zeng, Guisheng Zhang, Xiangqing Xu, Liang Ren
  • Patent number: 9994578
    Abstract: The present invention relates to a new benzodiazepine derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and use thereof. The benzodiazepine derivative and the pharmaceutically acceptable salt thereof of the present invention have obvious anesthetic effect and low toxicity in body, thereby enhancing the medication safety. The benzodiazepine derivative and the pharmaceutically acceptable salt thereof of the present invention have sedative, hypnotic, and anesthetic effect, and can be used as sedative, hypnotic, and anesthetic drugs.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: June 12, 2018
    Assignee: JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD
    Inventor: Qingeng Li
  • Patent number: 9650390
    Abstract: The present invention discloses a class of water soluble taxane derivatives, a method for treating tumor using the same, use thereof as anti-tumor drugs and use thereof in the preparation of anti-tumor drugs. The water soluble taxane derivatives have the general formula (I-1), (I-2) or (I-3): wherein, R1 is H or methyl; R2 is H, methyl or acetyl; R3 is phenyl or OC(CH3)3; X is H, C1-6 alkyl or F; Y is F or C1-6 alkyl substituted with one or more F; n is 1, 2, 3, 4, 5 or 6; W is NR4R5.A or R4 and R5 are each independently H, C1-6 alkyl optionally substituted with phenyl, or C3-6 cycloalkyl; m is 0, 1, 2 or 3; and A is a pharmaceutically acceptable acid.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: May 16, 2017
    Assignee: JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD
    Inventors: Qingeng Li, Tao Wang, Gang Chen, Yuanzhong Wang, Wei Mao, Lingguo Zeng, Tong Wu, Dahai Chen
  • Patent number: 9643917
    Abstract: The present invention discloses a class of water-soluble propofol derivatives, preparation method thereof, anesthetization method using the same, use thereof as prodrugs and use thereof in the preparation of intravenous anesthetics. The water-soluble propofol derivatives have the general formula (I); wherein X is H or F, Y is F or alkyl substituted by one or more F, n is 1, 2, 3, 4, 5 or 6, W is W1 or W2; W1 is NR1R2.A or R1 and R2 are each independently H, alkyl optionally substituted with phenyl, or cycloalkyl, m is 0, 1, 2 or 3, A is a pharmaceutically acceptable acid, W2 is COOM1/t or OPO3(M)2/t or PO3(M)2/t; M is a metal ion, an ammonium ion or a basic amino acid cation which can form a salt with an acid radical; t is the charge number of M.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: May 9, 2017
    Assignee: JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD
    Inventors: Qingeng Li, Tao Wang, Tong Wu, Lingguo Zeng, Yuanzhong Wang, Wei Mao, Gang Chen